Terminated OBSERVATIONAL NCT00899093

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy

Sponsor: Gynecologic Oncology Group

Conditions Fallopian Tube Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Malignant Ovarian Brenner Tumor Malignant Ovarian Clear Cell Tumor Malignant Ovarian Endometrioid Tumor Malignant Ovarian Mixed Epithelial Tumor Malignant Ovarian Mucinous Tumor Malignant Ovarian Neoplasm Malignant Ovarian Serous Tumor Malignant Ovarian Transitional Cell Tumor Ovarian Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Stage IIIA Fallopian Tube Cancer Stage IIIA Ovarian Cancer Stage IIIA Primary Peritoneal Cancer Stage IIIB Fallopian Tube Cancer Stage IIIB Ovarian Cancer Stage IIIB Primary Peritoneal Cancer Stage IIIC Fallopian Tube Cancer Stage IIIC Ovarian Cancer Stage IIIC Primary Peritoneal Cancer Stage IV Fallopian Tube Cancer Stage IV Ovarian Cancer Stage IV Primary Peritoneal Cancer Undifferentiated Fallopian Tube Carcinoma Undifferentiated Ovarian Carcinoma

Interventions Cytology Specimen Collection Procedure Laboratory Biomarker Analysis

Updated 9 times since 2017 Last updated: May 21, 2018 Started: Sep 30, 2007 Primary completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Gynecologic Oncology Group

More terminations from Gynecologic Oncology Group

Other Fallopian Tube Adenocarcinoma trials with similar outcome

Browse all Fallopian Tube Adenocarcinoma trials

Listed as NCT00899093, this observational or N/A phase trial focuses on Fallopian Tube Adenocarcinoma and Fallopian Tube Clear Cell Adenocarcinoma and remains terminated or withdrawn. Sponsored by Gynecologic Oncology Group, it has been updated 9 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated
Sep 2024 — Sep 2025 [monthly]

Terminated
Jul 2024 — Sep 2024 [monthly]

Terminated
Feb 2021 — Jul 2024 [monthly]

Terminated
Jan 2021 — Feb 2021 [monthly]

Terminated

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated

Status: Active Not Recruiting → Terminated
Apr 2018 — Jun 2018 [monthly]

Active Not Recruiting

Phase: NA → None
Jun 2017 — Apr 2018 [monthly]

Active Not Recruiting NA
Jan 2017 — Jun 2017 [monthly]

Active Not Recruiting NA

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Akron, United States , Alton, United States , Amarillo, United States , Anderson, United States , Ann Arbor, United States , Atlanta, United States , Baton Rouge, United States , Billings, United States , Boise, United States and 89 more locations